Pharmaceutical Giant Sanofi Treated 24 COVID-19 Patients Using Malaria

Neither drug is a proven treatment for COVID-19, the deadly disease caused by the coronavirus, however, and neither is likely to be publicly available in the near future.

Like previous White House briefings, this one suffered from conflicting messages from the president and his advisers. The Food and Drug Administration has approved hydroxychloroquine and chloroquine for use against COVID-19.

But Trump falsely suggested to reporters that the FDA had just cleared the drug specifically for the viral pandemic spreading in communities across the U.S. That would mean that the drug had met the FDA's standards for safety and effectiveness. "I have great hope for how we're going to come out of this situation".

"We need to make sure that this sea of new treatments - we'll get the right drug to the right patient at the right dosage at the right time", he said, explaining that the right drug may be available but it may not be in the right dosage, "and that may do more harm than good".

Lab studies (including research published in Virology Journal in 2005) show that chloroquine is effective at preventing as well as treating the virus that causes severe acute respiratory syndrome (SARS), which is caused by another strain of coronavirus.

"We could collect the blood, this is a possible treatment, not a proven treatment, and concentrate that".

COVID-19: Alberta school closures, if implemented, could last until September
I know some Albertans will wonder if these restrictions were truly necessary. "As I have repeatedly said, this is our new normal". Hinshaw delivered an update on the novel coronavirus on March 16 via video conference after reporting mild symptoms of a cold.


"A drug called chloroquine, and some people would add to it, hydroxy, Hydroxychloroquine, this is a common malaria drug".

"We now work with four different distributors and as of today are unable to order any chloroquine or hydroxychloroquine", which are on back order, David Light, chief executive of online pharmacy Valisure, said in an emailed statement.

French health minister Olivier Véran has said that new tests will now go ahead in order to evaluate the results by Professor Raoult, in an attempt to independently replicate the trials and ensure the findings are scientifically robust enough, before any possible decision might be made to roll any treatment out to the wider public. "We want to do that in the setting of a clinical trial - a large, pragmatic clinical trial - to actually gather that information and answer the question that needs to be asked and answered". The drug has been used in a small number of patients with COVID-19 in an experimental manner, according to Gilead.

She also emphasized that the outbreak remains highly localized in the USA, with more than 50% of cases coming from three states, "which is why we continue to prioritize testing in those states". "The big advantage of chloroquine is it's available for use in people, it's a pretty safe drug, and it's not terribly expensive".

36 patients - including 20 treated individuals and 16 infected controls - were enrolled in the study, led by Didier Raoult, an infectious disease expert from l'Institut Hospitalo-Universitaire in Marseille.

Regeneron Pharmaceuticals says it will lanch a study of Kevzara, its rheumatoid arthritis drug that also targets interleukin-6, against the coronavirus.

  • Ismael Montgomery